Diagnostic tests for medullary thyroid carcinoma: an umbrella review.


Journal

Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444

Informations de publication

Date de publication:
08 2023
Historique:
received: 11 01 2023
accepted: 08 02 2023
medline: 28 6 2023
pubmed: 7 3 2023
entrez: 6 3 2023
Statut: ppublish

Résumé

To summarize the more robust evidence about the performance of tools useful for diagnosis of medullary thyroid carcinoma (MTC) such as calcitonin (Ctn) and other circulating markers, ultrasound (US), fine-needle aspiration (FNA), and other imaging procedures. This systematic review of systematic reviews was carried out according to a predefined protocol. A search string was created. An electronical comprehensive search of literature was performed on December 2022. Quality assessment of eligible systematic reviews was performed and main findings were described. Twenty-three systematic reviews were included and several findings were achieved. Ctn is the most reliable diagnostic marker of MTC with no evidence of improvement with stimulation test. CEA doubling time is more reliable than Ctn in identifying MTC with poorer prognosis. US sensitivity is suboptimal in MTC and only just over half of cases are at high risk according to Thyroid Imaging And Reporting Data Systems. Cytology can correctly detect MTC in just over half of cases and measuring Ctn in washout fluid from FNA is necessary. PET/CT is useful for detecting recurrent MTC. Future guidelines of both thyroid nodule management and MTC diagnosis should consider these evidence-based data.

Identifiants

pubmed: 36877452
doi: 10.1007/s12020-023-03326-6
pii: 10.1007/s12020-023-03326-6
pmc: PMC10293444
doi:

Substances chimiques

Calcitonin 9007-12-9

Types de publication

Journal Article Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

183-193

Informations de copyright

© 2023. The Author(s).

Références

Endocrine. 2022 Feb;75(2):330-337
pubmed: 34748168
Cochrane Database Syst Rev. 2020 Mar 16;3:CD010159
pubmed: 32176812
Oncology. 2021;99(7):422-432
pubmed: 33878761
Horm Metab Res. 2021 Jun;53(6):355-363
pubmed: 34154026
Clin Chem Lab Med. 2015 Sep 1;53(10):1507-14
pubmed: 25781697
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):61-77
pubmed: 31482429
Rev Endocr Metab Disord. 2021 Jun;22(2):453-460
pubmed: 32959174
BMC Endocr Disord. 2019 May 29;19(Suppl 1):45
pubmed: 31142313
Am J Surg. 2022 Aug;224(2):670-675
pubmed: 35382933
J Clin Endocrinol Metab. 2021 Nov 19;106(12):3634-3643
pubmed: 34382653
Minerva Endocrinol. 2017 Sep;42(3):238-247
pubmed: 27808486
Endocrine. 2012 Dec;42(3):535-45
pubmed: 22527889
Acad Radiol. 2012 Oct;19(10):1290-9
pubmed: 22819076
Endokrynol Pol. 2017;68(4):434-437
pubmed: 28585679
Clin Endocrinol (Oxf). 2010 Apr;72(4):534-42
pubmed: 19563448
J Natl Compr Canc Netw. 2010 May;8(5):512-30
pubmed: 20495082
Pathol Res Pract. 2022 Jan;229:153694
pubmed: 34929598
Endocrine. 2022 Jun;77(1):80-85
pubmed: 35391593
J Thyroid Res. 2019 Jul 7;2019:1893047
pubmed: 31360432
Endocrine. 2022 Jan;75(1):33-39
pubmed: 34606057
Anticancer Res. 2016 Aug;36(8):3803-10
pubmed: 27466480
Thyroid. 2009 Jun;19(6):565-612
pubmed: 19469690
J Endocrinol Invest. 2010;33(5 Suppl):51-6
pubmed: 20543551
Eur J Endocrinol. 2006 Jun;154(6):787-803
pubmed: 16728537
Clin Nucl Med. 2020 May;45(5):341-348
pubmed: 32049723
Endocr Connect. 2021 Mar;10(3):358-370
pubmed: 33638941
Endokrynol Pol. 2014;65(4):314-8
pubmed: 25185855
Clin Endocrinol (Oxf). 2022 Nov;97(5):532-540
pubmed: 35419855
Endocrinol Metab (Seoul). 2018 Jun;33(2):204-210
pubmed: 29947178
Diagn Cytopathol. 2016 Jan;44(1):45-51
pubmed: 26481456
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Thyroid. 2016 Aug;26(8):1093-100
pubmed: 27267210
Thyroid. 2015 Jun;25(6):567-610
pubmed: 25810047
Endocr Relat Cancer. 2015 Jun;22(3):R157-64
pubmed: 25934688
Clin Endocrinol (Oxf). 2015 Feb;82(2):280-5
pubmed: 25047365
Hormones (Athens). 2017 Oct;16(4):362-372
pubmed: 29518756
J Med Imaging Radiat Oncol. 2012 Apr;56(2):136-42
pubmed: 22498184

Auteurs

Pierpaolo Trimboli (P)

Clinic of Endocrinology and Diabetology, Lugano and Mendrisio Regional Hospital, Ente Ospedaliero Cantonale, 6500, Bellinzona, Switzerland. pierpaolo.trimboli@eoc.ch.
Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900, Lugano, Switzerland. pierpaolo.trimboli@eoc.ch.

Caterina Mian (C)

Operative Unit of Endocrinology, Department of Medicine-DIMED, University of Padova, Padova, Italy.

Arnoldo Piccardo (A)

Nuclear Medicine Department, E.O. "Ospedali Galliera", 16128, Genoa, Italy.

Giorgio Treglia (G)

Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6900, Lugano, Switzerland.
Faculty of Biology and Medicine, University of Lausanne, 1011, Lausanne, Switzerland.
Division of Medical Education and Research, Ente Ospedaliero Cantonale, 6500, Bellinzona, Switzerland.

Articles similaires

Humans Patellofemoral Pain Syndrome Self-Management Athletes Systematic Reviews as Topic
Humans Perioperative Period Systematic Reviews as Topic Regression Analysis Developing Countries

Anhui Zhu, Xiaoyan Hou, Na Guo et al.
1.00
Humans Carcinoma, Renal Cell Vena Cava, Inferior Male Female
Humans Female Breast Neoplasms Middle Aged Positron Emission Tomography Computed Tomography

Classifications MeSH